ASX biotech Anteris Technologies has revealed flawless results from trials of its artificial heart valve. Read that and more in our health wrap.
Anteris has just presented the latest data from the DurAVR First-In-Human Study at the TVT Conference.
Results show that DurAVR THV continues to maintain excellent haemodynamic performance at one year and 30-day time points.
For the latest health news, sign up here for free Stockhead daily newsletters
During the study, DurAVR THV was successfully implanted in 100 per cent of the patients, with no device-related complications.
The first 12 patients have completed their one-year follow-up, and results demonstrated sustained haemodynamic performance.
All 20 study patients, meanwhile, have reached their 30-day follow-up, showing results consistent with data previously reported.
“This is another step forward as we continue building upon the body of evidence that supports the use of DurAV THV in patients with aortic stenosis,” said chief medical officer, Dr Chris Meduri.
The DurAVR is a 3D single-piece aortic heart valve replacement which the company believes will be a game-changer.
MORE FROM STOCKHEAD: FDA boost for skin-defect treatment| ASX small cap health stocks paying dividends| 4D lung imaging tech breath of fresh air
Imugene progresses to next cohort
Imugene (ASX:IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of cancer-killing virus CF33-hNIS (VAXINIA) has progressed to the next cohort level.
The trial has now cleared cohort 3, and opened cohort 4 of the IV arm of the monotherapy dose escalation.
In addition, cohort 1 of the IV arm of the combination study with Pembrolizumab has also been cleared, allowing cohort 2 to be opened.
Nyrada’s new lead drug
Nyrada (ASX:NYR) says its new brain injury drug candidate NYR-BI03 will be advanced instead of NYR-BI02, due to demonstrated superior potency and safety profile, overcoming limitations identified with NYR-BI02 during preclinical studies.
Visit Stockhead, where ASX small caps are big deals
The company said it had reviewed more than 200 available compounds generated by NYR-BI03, a closely related analogue of NYR-BI02.
The study indicated that NYR-BI03 had a superior safety profile, along with better potency on the TRPC ion channel protein target.
This means that NYR-BI03 has now become Nyrada’s new lead brain injury drug candidate.
Starpharma boss to exit
Starpharma (ASX:SPL) CEO Dr Jackie Fairley has announced that she will retire in 2024, after being in the position since 2006.
The board said Fairley would remain in the role until a successor was ready to start.
This content first appeared onstockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox.Click here